[A21-101] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 03.02.2022
Project no.:
A21-101
Commission:
Commission awarded on 01.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with multiple myeloma
Result of dossier assessment:
- Patients who have already received 1 prior therapy with a proteasome inhibitor and lenalidomide and who were refractory to lenalidomide: added benefit not proven.
- Patients who have already received ≥ 2 prior therapies containing lenalidomide and a proteasome inhibitor and who showed disease progression under or after the last therapy: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2022-02-03 A G-BA decision was published.